Janelle Bradley

NCCN Updates Clinical Practice Guideline for Central Nervous System Cancers
Guideline Updates
NCCN Updates Clinical Practice Guideline for Central Nervous System Cancers
03/24/2021
NCCN released an update to its clinical practice guideline for central nervous system cancers, adding lorlatinib as a category 2A recommendation for brain metastases from NSCLC.
NCCN released an update to its clinical practice guideline for central nervous system cancers, adding lorlatinib as a category 2A recommendation for brain metastases from NSCLC.
NCCN released an update to its...
03/24/2021
Journal of Clinical Pathways
Conference Coverage
Fedratinib Demonstrates Promising Efficacy in MDS/MPN and Chronic Neutrophilic Leukemia
12/09/2023
Data from a phase 2 trial show fedratinib demonstrates promising clinical activity in patients with MDS/MPN and chronic neutrophilic leukemia.
Data from a phase 2 trial show fedratinib demonstrates promising clinical activity in patients with MDS/MPN and chronic neutrophilic leukemia.
Data from a phase 2 trial show...
12/09/2023
Oncology
Conference Coverage
Third-Line Chemotherapy With or Without Trastuzumab-Based Therapy for Metastatic Breast Cancer
12/06/2021
The inclusion of trastuzumab-based therapy with chemotherapy was associated with improved survival outcomes compared with chemotherapy alone for the third-line treatment of metastatic breast cancer.
The inclusion of trastuzumab-based therapy with chemotherapy was associated with improved survival outcomes compared with chemotherapy alone for the third-line treatment of metastatic breast cancer.
The inclusion of...
12/06/2021
Journal of Clinical Pathways
Conference Coverage
Oncologist vs Urologist Treatment Decision-Making for Metastatic Castration–Sensitive Prostate Cancer in the United States
06/03/2022
Study findings presented at the 2022 ASCO Annual Meeting reveal oncologists’ and urologists’ reasons for underutilization of treatment intensification for patients with metastatic castration–sensitive prostate cancer.
Study findings presented at the 2022 ASCO Annual Meeting reveal oncologists’ and urologists’ reasons for underutilization of treatment intensification for patients with metastatic castration–sensitive prostate cancer.
Study findings presented at the...
06/03/2022
Journal of Clinical Pathways
Conference Coverage
Real-World Incidence of Thromboembolic Events in Patients With Metastatic Breast Cancer Treated With Ribociclib
12/07/2021
Study findings show patients with metastatic breast cancer treated with ribociclib plus aromatase inhibitors or fulvestrant are not at higher risk for thromboembolic events.
Study findings show patients with metastatic breast cancer treated with ribociclib plus aromatase inhibitors or fulvestrant are not at higher risk for thromboembolic events.
Study findings show patients...
12/07/2021
Journal of Clinical Pathways
News
Long-term Survival After Autologous Transplantation Among Patients With MCL
02/23/2022
Study findings confirm the long-term efficacy of autologous hematopoietic stem cell transplantation for treating MCL.
Study findings confirm the long-term efficacy of autologous hematopoietic stem cell transplantation for treating MCL.
Study findings confirm the...
02/23/2022
Journal of Clinical Pathways
News
Biomarker Testing Rates and Turnaround Times for Patients With NSCLC Receiving First-Line Therapy in The US Oncology Network
04/01/2022
Study findings revealed that 90% of patients with metastatic NSCLC in The US Oncology Network received ≥1 biomarker test prior to first-line treatment, though
Study findings revealed that 90% of patients with metastatic NSCLC in The US Oncology Network received ≥1 biomarker test prior to first-line treatment, though
Study findings revealed that 90%...
04/01/2022
Journal of Clinical Pathways
Conference Coverage
Pomalidomide vs Carfilzomib for Patients With MM at First Relapse
03/25/2022
Nina Shah, MD, argues in favor of pomalidomide over carfilzomib for patients with MM at first relapse in the real-world setting at the 2022 Great Debates and Updates in Hematologic Malignancies meeting.
Nina Shah, MD, argues in favor of pomalidomide over carfilzomib for patients with MM at first relapse in the real-world setting at the 2022 Great Debates and Updates in Hematologic Malignancies meeting.
Nina Shah, MD, argues in favor...
03/25/2022
Oncology
Conference Coverage
Oncology Clinical Pathways Benchmarking Survey 2021 Results
09/29/2021
Winston Wong, PharmD, editor-in-chief of the Journal of Clinical Pathways, presented findings from the 2021 Oncology Clinical Pathways Benchmarking Survey.
Winston Wong, PharmD, editor-in-chief of the Journal of Clinical Pathways, presented findings from the 2021 Oncology Clinical Pathways Benchmarking Survey.
Winston Wong, PharmD,...
09/29/2021
Clinical Pathways
Conference Coverage
Evolving Treatment Landscape for Metastatic Hormone-Sensitive Prostate Cancer
03/30/2022
In a presentation at the 2022 Great Debates and Updates in Genitourinary Oncology meeting, Oliver Sartor, MD, discussed the evolving treatment landscape for metastatic hormone-sensitive prostate cancer.
In a presentation at the 2022 Great Debates and Updates in Genitourinary Oncology meeting, Oliver Sartor, MD, discussed the evolving treatment landscape for metastatic hormone-sensitive prostate cancer.
In a presentation at the 2022...
03/30/2022
Oncology

Upcoming Events

Advances in Inflammatory Bowel Disease Regionals
April 5 ⁠–⁠ April 6
Rx summit logo
April 21 ⁠–⁠ April 24
April 29 ⁠–⁠ April 30
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 4
Psych Congress Regionals
May 1 ⁠–⁠ May 2
May 7 ⁠–⁠ May 9
NEI Congress
May 8 ⁠–⁠ May 10
Dermatology Week
May 14 ⁠–⁠ May 16
Senior Living Executive Conference
May 19 ⁠–⁠ May 21
May 28 ⁠–⁠ May 31
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use